argenx SE · NASDAQ (us_market)
Healthcare · Biotechnology · Netherlands
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-11-17$929.61 RISE2026-03-20$663.93 PEAK2026-04-17$849.04 151d | -28.6% 123d | Missed | Missed | — | — | +27.9% 28d | Missed |
DROP2025-05-05$656.65 RISE2025-06-18$537.92 PEAK2025-09-08$768.00 126d | -18.1% 44d | Missed | Missed | — | — | +42.8% 82d | Missed |
DROP2025-02-05$671.74 RISE2025-05-14$532.27 PEAK2025-08-04$690.32 180d | -20.8% 98d | Missed | Missed | — | — | +29.7% 82d | Missed |
DROP2025-02-05$671.74 RISE2025-04-10$546.22 PEAK2025-05-05$656.65 89d | -18.7% 64d | Missed | Missed | — | — | +20.2% 25d | Missed |
DROP2023-09-15$527.98 RISE2023-12-20$338.91 PEAK2024-01-08$413.29 115d | -35.8% 96d | Missed | Missed | — | — | +21.9% 19d | Missed |
DROP2023-01-12$403.65 RISE2023-03-08$334.23 PEAK2023-05-19$422.58 127d | -17.2% 55d | Missed | Missed | — | — | +26.4% 72d | Missed |
DROP2021-12-30$353.03 RISE2022-05-09$269.58 PEAK2022-07-05$382.11 187d | -23.6% 130d | Missed | Missed | — | — | +41.7% 57d | Missed |
DROP2021-12-30$353.03 RISE2022-03-08$263.59 PEAK2022-04-07$328.77 98d | -25.3% 68d | Missed | Missed | — | — | +24.7% 30d | Missed |
DROP2021-12-30$353.03 RISE2022-01-27$254.45 PEAK2022-04-07$328.77 98d | -27.9% 28d | Missed | Missed | — | — | +29.2% 70d | Missed |
DROP2021-09-03$350.58 RISE2021-11-23$272.01 PEAK2021-12-30$353.03 118d | -22.4% 81d | Missed | Missed | — | — | +29.8% 37d | Missed |
DROP2021-02-11$380.31 RISE2021-05-10$257.11 PEAK2021-06-14$319.92 123d | -32.4% 88d | Missed | Missed | — | — | +24.4% 35d | Missed |
DROP2020-07-20$272.51 RISE2020-09-10$215.51 PEAK2020-12-01$289.38 134d | -20.9% 52d | Missed | Missed | — | — | +34.3% 82d | Missed |
DROP2020-01-09$165.23 RISE2020-03-16$108.83 PEAK2020-06-02$232.72 145d | -34.1% 67d | Missed | Missed | — | — | +113.8% 78d | Missed |
This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology.
During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41.
European equities traded in the US as American depositary receipts were tracking lower late Wednesda
argenx (ENXTBR:ARGX) received FDA approval expanding Vyvgart's label to cover all adult patients with generalized myasthenia gravis. The expanded indication broadens access to Vyvgart across the full adult gMG population in the United States. The company appointed Karen Massey as Chief Executive Officer, marking a leadership transition at argenx. For investors watching ENXTBR:ARGX, the FDA label expansion puts Vyvgart more squarely at the center of argenx's neuromuscular portfolio. The...
argenx SE (NASDAQ:ARGX) is one of the 10 Best European Growth Stocks to Buy. On May 15, 2026, Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on argenx SE (NASDAQ:ARGX) to $1,059 from $1,007 while maintaining an Outperform rating on the shares. Earlier in the week, BofA analyst Tazeen Ahmad raised the firm’s […]
argenx (ARGX) update: VYVGART drives 63% YoY Q1 2026 growth and 30% margins; FDA gMG expansion boosts TAM.
Immunovant reports clinically meaningful trial results for its lead drug candidate. That’s good news for Roivant Sciences.
European equities traded in the US as American depositary receipts were trending lower late Tuesday
2026-05-15. The following slide deck was published by argenx SE in conjunction with their 2026 Q1 earnings call.
Evercore ISI Group analyst Gavin Clark-Gartner maintains argenx (NASDAQ:ARGX) with a Outperform and raises the price target from $1007 to $1059.
argenx’s fair value estimate has shifted only slightly, with the blended target moving from €842.55 to €845.01. This signals a finely tuned update rather than a wholesale reset. That small move reflects a tug of war between analysts trimming targets on more cautious assumptions and others lifting or reaffirming higher fair value views based on Vyvgart, spending plans and the late stage pipeline. As you read on, you will see how these cross currents are shaping the evolving narrative around...
argenx SE (NASDAQ:ARGX) is one of the 8 Most Promising Biotech Stocks to Buy Now. On May 9, argenx SE (NASDAQ:ARGX) reported that the U.S. Food and Drug Administration approved a label expansion for Vyvgart and Vyvgart Hytrulo. It extended use across all serotypes of adult generalized myasthenia gravis, including anti-AChR, anti-MuSK, anti-LRP4, and triple […]
HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.
argenx SE (ARGX) Bank of America Global Healthcare Conference 2026 May 12, 2026 1:40 PM EDTCompany ParticipantsKaren Massey - CEO & Executive...
AbCellera Biologics (NASDAQ:ABCL) said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued preparation for multiple clinical catalysts expected over the next two years. President and CEO Dr. Carl
Argenx shares rise after FDA expands VYVGART approval to all adult gMG patients, widening the drug's market opportunity.
VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple
Guggenheim analyst Yatin Suneja maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $1120 to $1135.
Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1247 to $1260.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ARGX | +6.70% | +10.47% | -0.59% | +45.83% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +3.73% | +16.18% | +2.85% | +33.14% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 4.99M | $3.64B | 0.19% | Trimmed-10.8% | 2026-03-31 |
| Wellington | fundamental | 1.02M | $745.92M | 0.14% | Added+50.4% | 2026-03-31 |
| TwoSigma | quant | 109.1K | $79.69M | 0.06% | Trimmed-57.8% | 2026-03-31 |
| DEShaw | quant | 52.1K | $38.06M | 0.02% | Added+14.5% | 2026-03-31 |
| StateStreet | passive | 5.1K | $3.73M | 0.00% | Added+8.0% | 2026-03-31 |
| TRowePrice | fundamental | 3.37M | $2.46M | 0.28% | Unchanged | 2026-03-31 |
| Bridgewater | macro | 1.2K | $886.52K | 0.00% | New | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-23upcoming | 5.21 | — | — |
| 2026-05-07 | 4.19 | 4.70 | +11.98% |
| 2026-02-26 | 5.20 | 6.79 | +30.74% |
| 2025-10-30 | 3.54 | 4.44 | +25.52% |
| 2025-07-31 | 2.61 | 3.26 | +24.65% |
| 2025-05-08 | 2.05 | 2.27 | +10.64% |
| 2025-02-27 | 1.70 | 0.71 | -58.04% |
| 2024-10-31 | 0.06 | 1.28 | +2138.78% |
| 2024-07-25 | -0.99 | 0.41 | +141.80% |
| 2024-05-09 | -0.81 | -0.97 | -19.93% |
| 2024-02-29 | -1.16 | -1.55 | -33.28% |
| 2023-10-31 | -1.34 | -1.18 | +11.92% |
| 2023-07-27 | -1.65 | -1.53 | +7.75% |
| 2023-05-04 | -2.12 | -0.47 | +77.83% |
| 2023-03-02 | -2.83 | -0.66 | +76.71% |
| 2022-10-27 | -3.58 | -4.26 | -19.05% |